Abstract Rapid tests for diagnosis of influenza are valuable assets in the management of influenza in pediatric patients. However, test performance fluctuates with virus subtypes. We assessed the test characteristics of Influenzatop®, a rapid immunochromatographic influenza A and B test, in detecting pandemic 2009 influenza A (H1N1) in children up to 18 years of age, using reverse transcriptase polymerase chain reaction (RT-PCR) as the gold standard. Three hundred and one pediatric outpatients with influenzalike illness were included into the study. Overall sensitivity of Influenzatop® was 64% (95% confidence interval (CI) 56-71%) but increased to 92% (95% CI, 80-97%) when performed between 24 and 48 h after onset of symptoms. Positive Influenzatop® results among RT-PCR-positive patients were associated with higher viral load. No significant variation in test performance could be detected when analyzed by age and high versus low prevalence period. Overall test specificity was 99% (95% CI, 95-100%); positive and negative predictive values were 98% (95% CI, 93-99%) and 70% (95% CI, 63-76%), respectively. Conclusion: Influenzatop® rapid influenza test is a sound tool in the diagnosis of H1N1 in pediatric patients when employed 24-48 h after onset of symptoms.
Introduction
On April 29, 2009, the first pandemic (H1N1) 2009 influenza case was reported in Switzerland. In Geneva canton, 2,377 cases were reported until December 2009 for a total population of 453,292, and around 57% occurred in the pediatric age group [16] . Often decisions about treatment, prophylaxis, and infection control measures have to be taken by the pediatric provider before real-time reverse transcriptase polymerase chain reaction (RT-PCR) results are available. A variety of rapid tests for the diagnosis of influenza are at hand and they are used routinely in children. For management of seasonal influenza in pediatric patients, rapid tests have been shown to reduce prescription of laboratory test, radiographic studies, and antibiotics [4, 10, 12] . However, their performance fluctuates with virus subtypes and has indeed been reported to be poorer for nonhuman strains [6, 17] . It is hence crucial to understand the characteristics of commercial tests used for detection of pandemic (H1N1) 2009 virus because it will probably continue to circulate in the population in addition to the seasonal strains in the coming years. We initially used both of QuickVue Influenza A + B® test (Quidel), a rapid test routinely used for rapid testing for seasonal influenza in our pediatric department at the University Children's Hospital Geneva (HUG), as well as Influenzatop® (ALL.DIAG, Strasbourg, France), a rapid immunochromatographic influenza A and B test, for rapid detection of pandemic (H1N1) 2009 virus in addition to routine RT-PCR testing. After an initial subset of patients has been identified, it appeared from published data and our own experience that sensitivity of QuickVue® was low to moderate [8] . In order to limit the number of nasal swab samples to be collected for each patient, we hence decided to only further assess the performance of Influenzatop® in our population. The objective of this analysis was to characterize Influenzatop® (ALL.DIAG, Strasbourg, France), a rapid immunochromatographic influenza A and B test, in detecting the pandemic (H1N1) 2009 virus among pediatric patients.
Materials and methods

Study population and testing strategy
Patients up to 18 years of age who were tested for pandemic (H1N1) 2009 virus using both Influenzatop® and RT-PCR between August 21 and December 16, 2009 were included. Information from two different patient subpopulations were used: the first population consisted of patients included into a pediatric H1N1 surveillance study conducted at HUG; the second population was composed of test results from routine testing at the Pediatric Emergency Division of HUG and at 13 participating outpatient sites. Inclusion criteria and testing procedure were identical for all subgroups. At HUG, a total of 591 pediatric patients were tested for H1N1 between August and December 2009; 216 cases were confirmed positive (Fig. 1) . The peak of the epidemic in Geneva was observed in November 2009 [16] . After November 21, 2009, the Swiss pediatric H1N1 consortium recommended discontinuation of routine testing for pandemic (H1N1) 2009 virus. Testing was subsequently limited to at-risk patients presenting influenza-like illness (ILI) as defined as fever ≥38°C plus upper or lower respiratory symptoms. At-risk categories were defined as follows: patients with severe or rapidly aggravating symptoms; patients hospitalized for respiratory infections; patients <12 months of age; patients with personal risk factors such as chronic cardiac conditions, severe asthma, cystic fibrosis, neuromuscular disease, and immunodeficiency; infants <2 years of age born <33 weeks of gestation or with birth weight <1,500 g; and patients in close contact with at-risk patients such as infants <6 months of age and pregnant women.
Sample collection and testing
For each patient, two specimens were collected by trained physicians. One foam-tipped nasal swab provided by the manufacturer was immediately tested with the Influenzatop® assay (ALL.DIAG, Strasbourg, France) according to the manufacturer's protocol [1] . One additional nasopharyngeal swab was placed in a viral transport medium, stored at 4°C, and sent off the same day for testing using RT-PCR. InfACDC, a protocol for identification and characterization of the pandemic 2009 influenza A (H1N1) virus strain provided by the Centers for Disease Control and Prevention (CDC), was used [19] . The threshold for detection of fluorescence above background was determined. For semiquantitative comparison of the amount of RNA template, i.e., viral load, the cycle threshold (Ct) of samples using InfACDC was compared. Ct is the cycle at which the fluorescence from a sample crosses the threshold for detection. Ct is thus inversely related to viral load.
Data analysis
The sensitivities, specificities, positive predictive values (PPV), and negative predictive values (NPV) of Influenzatop® were calculated using RT-PCR for pandemic (H1N1) 2009 virus as the gold standard test; 95% confidence (95% CI) intervals for proportions were produced with the Wilson score method [11] . Differences in proportions among subgroups were analyzed using chi-square tests. For normally distributed variables, difference in mean viral load between subgroups was assessed by ANOVA. For prediction of sensitivity, covariates were compared between Influenzatop®-negative and -positive patients within PCRpositive samples. Chi-square tests were used for categorical variables and t test for Ct. Logistic regression was performed to study independent influence of various factors on sensitivity. Ct was entered as a continuous variable whereas duration of symptoms and age were categorized. The final model was obtained through backward selection of variables displayed in Table 3 using the likelihood ratio test at the p<0.10 level. The performance of the predictive model was illustrated by the receiver-operating characteristic curve, as well as by sensitivity and specificity. All statistical tests are two-tailed and a p value of 0.05 was considered statistically significant. All computations were performed using SPSS version 15.0 (SPSS Inc.) and Excel 2003 (Microsoft Inc.). Informed consent was obtained at inclusion from patients participating in the H1N1 surveillance study (n=83). For the 116 patients tested routinely at HUG, consent was asked retrospectively via telephone interviews-4 of 116 patients refused participation in the study. This study was approved by the ethical committee of HUG. For patients included from routine testing at the 13 pediatric outpatient sites (n=94), anonymous data were sent to the investigators for analysis. The study was also approved by the ethical committee of Geneva County.
Results
Characteristics of the study population
Three hundred and one patients from the H1N1 surveillance study (n=84, 27.9%) and from routine testing at HUG as well as 13 outpatient sites (n=217, 72.1%) were included in the study. The age range of the patients tested was 7 days to 18 years (mean 6.8 years, SD 4.8 years, median 6.06 years); 50 patients (16.6%) were under 24 months of age. Age and sex characteristics were similar for the two patient subpopulations; patients tested in the context of H1N1 surveillance study presented slightly later into the illness ( Table 1) .
Performance of Influenzatop®
RT-PCR results for pandemic (H1N1) 2009 virus were positive in 164 samples (54%). Table 2 displays both the overall test characteristics for Influenzatop® for the detection of pandemic (H1N1) 2009 virus, as well as stratified by patient subpopulation, age, duration of symptoms, and prevalence phase. In our patient population, Influenzatop® had an overall sensitivity, specificity, PPV, and NPV of 64% (95% CI, 56-71%), 99% (95% CI, 95-1.00%), 98% (95% CI, 93-99%), and 70% (95% CI, 63-76%), respectively. As for the different patient subgroups, Influenzatop® showed a higher sensitivity and NPV in patients tested during routine testing: 69% versus 53% (chi-square 4.13 (p=0.042)) and 76% versus 54% (overall chi-square 7.55 (p=0.006)), respectively. No significant difference in specificity nor PPV could be detected: chi-square 0.48 (p=0.49) and 0.36 (p=0.55). Sensitivity, specificity, and PPV were not significantly different across age strata: overall chi-square-3.98 (p=0.14), 3.03 (p=0.22), and 0.41 (p=0.81), respectively.
However, a significant difference was found for NPV (overall chi-square 17.70, p=0.001): NPV was greater for children aged <1 and 1-5 years when compared to patients >5 years of age (88% and 78% versus 56%; chi-square 20.49 (p<0001), 9.73 (p=0.007), respectively). As for the duration of symptoms, sensitivity was significantly greater when the test was performed between 24 and 48 h after onset of symptoms (92%) when compared to within the first 12 h (35%, chi-square 21.78, p<0.0001), 12-24 h (66%, chisquare 18.20, p=0.0004), and after 48 h (59%, chi-square 9.53, p=0.023). No significant difference in specificity and PPV was detected when stratified by duration of symptoms (overall chi-square 2.31 (p=0.55), and 0.54 (p=0.91), respectively). NPV was significantly greater between 24 and 48 h after onset of symptoms (96%, overall chi-square 11.78, p = 0.008) when contrasted to ≤12 h (66%, chi-square 8.71, p=0.03) and 12-24 h (75%, chi-square 17.66, p=0.0005). The test performance within the peak period of the epidemic (weeks 45-48) was not different from that during weeks of lower prevalence in terms of sensitivity, specificity, and PPV (chi-square 0.54 (p=0.46), 1.88 (p=0.17), and 0.48 (p=0.52), respectively). A greater NPV was observed in weeks of lower prevalence (93%) versus during the peak of the epidemic (64%, chi-square 24.04, p<0.0001).
For prediction of the probability of testing positive with Influenzatop® among RT-PCR-positive patients, hence an indicator of sensitivity, binary logistic regression was performed. The following variables (Table 3) were evaluated for the development of the prediction model: age, duration of symptoms, Ct, patient subgroup, as well as high versus low prevalence season. These variables showed no significant correlation. From these variables, duration of symptoms and Ct made statistically significant contribution to the prediction (Table 4) . Receiver-operating characteristic curve for the predictive model had an area under the curve of 0.78 (95% CI, 0.73-0.84) with an optimal sensitivity and specificity of 77% and 85%, respectively. In terms of viral load, RT-PCR-positive samples that yielded positive results in the rapid test reached threshold after a mean of 22.97 cycles (SD±3.40). This contrasted with a significantly greater Ct of 25.77 (SD±5.02) in the rapid test-negative group. These results thus indicate an Moreover, positive test results are especially useful in the management of patients presenting with febrile illness that are at low risk for bacterial co-infection (i.e., most patients above 3 months of age). On site confirmation of infection with pandemic (H1N1) 2009 virus in this patient group could prevent overuse of antibiotics. On the other hand, rapid testing in patients that are not eligible for RT-PCR testing allows considering antiviral treatment with neuraminidase inhibitor. Treatment during the first 2 days of symptoms has been shown to shorten influenza symptoms and prevent lower respiratory tract complication in influenza cases [9] . With regards to other commercial tests-although comparison has to be qualified given that data were only available from published data-we found that performance of Influenzatop® was similar to that of QuickVue®-65%, 95% CI 58.5-71.4% but higher when compared to BinaxNOW Influenza A&B® (Iverness Medical)-45%, 95% CI 43.3-46.3% [3, 8] . Sensitivity of Influenzatop® was higher when performed between 24 and 48 h post onset of symptoms compared to 74.2% (95% CI, 62-84.2) with QuickVue® [8] . Sensitivity of Influenzatop® was about 7% points higher contrasted to that estimated for direct fluorescence antibody assay (57.3%) in pediatric patients presenting with ILI [14] . In a large study assessing multiple tests, sensitivities of BinaxNOW® and 3MA + B® as compared to R-Mix culture for the detection of pandemic (H1N1) 2009 virus were 9.6% and 40%, respectively. However, in the latter study, the patient population included adults (mean age 13.7 years, range 2 weeks to 97 years) [7] .
Influenzatop® rapid test has neither been evaluated in the pediatric population nor for pandemic (H1N1) 2009 virus. The test was reported by the manufacturer to be 98.3% sensitive and 90.1% specific in the detection of influenza A in nasal swabs compared to viral isolation in adults [1] . This divergence from test characteristics observed in our study may be due to variation of performance of rapid influenza detection tests by virus subtype. Sensitivity of rapid tests has indeed been reported to be poorer for the nonhuman pandemic (H1N1) 2009 viruses [6, 8, 14, 15, 17] .
Viral load, as indicated by a lower number of RT-PCR cycles needed to reach threshold (Ct), was a positive predictor for true positive rapid test results when controlling for age and duration of symptoms. This goes in line with the results assessing the performance of BinaxNOW Influenza A&B Rapid Test® in PCR-positive clinical specimens [3, 5] . A positive correlation between sensitivity and viral load has also been found in studies assessing rapid tests during a regular influenza season [3] .
Sensitivity was highest when the test was performed between 24 and 48 h. This correlated with a higher viral load in patients diagnosed 12-48 h post onset of symptoms when compared to patients presenting after 48 h. This observed variation in sensitivity is similar to that found for QuickVue® which was found to be 59.7% sensitive on day 1 compared to 76.9%, 79.5%, and 54.5% on days 2, 3, and 4, respectively [3] .
Additionally, in a study among adult patients, an immunochromatographic rapid test was not found to be Table 4 Results of binary logistic regression model for sensitivity sufficiently sensitive within the 24 h of fever onset owing to low viral load [18] . However, in other studies among adult patients, no significant difference between presentation within the first 24 h or later could be detected [3, 13] . In influenza volunteer challenge studies, peak viral load has been reported 24-48 h following viral inoculation [2] . No such data exist for children or elderly subjects, but epidemiologic studies suggest that the natural history might differ. It is possible that children are symptomatic at relatively low viral loads [18] . Regarding the patient population of this study, only a subgroup of at-risk patients or patients with severe symptoms was tested after November 21, 2009. One might thus assume that viral load in this group may already be high early into symptomatic illness when compared to studies in the general pediatric population. However, the majority of patients (81%) were included before implementation of restricted testing and our patient sample can hence still be considered representative for the general pediatric population. There are several limitations to this study. The study was performed in one region only and in a limited study population. Testing in 19% of patients was limited to at-risk patients and patients presenting with severe symptoms. Due to this selection bias, prevalence of disease may be different in the general pediatric population; the positive and negative predictive values of any test are dependent on the prevalence of disease. Additionally, these values would diverge at different levels of circulation of seasonal influenza and/or pandemic (H1N1) 2009. Performance of Influenzatop® was compared to RT-PCR results with InfACDC primers only; results may be different when other primers are used as a reference standard.
In conclusion, regular assessment of test performance of rapid influenza tests is essential given the continuous antigenic drift of the influenza virus; performance may vary by brand and by virus subtype. When comparing Influenzatop® to that of QuickVue Influenza A + B® and BinaxNOW Influenza A&B® assessed in previous studies, performance of Influenzatop® appears comparable in general but higher when employed between 24 and 48 h post onset of symptoms [3, 8, 14] . Especially when employed between 24 and 48 h after onset of symptoms, Influenzatop® can be a valuable asset in the management of pediatric H1N1 patients. Rapid testing may reduce overuse of antibiotics and can be a helpful adjuvant in the decision about treatment and follow-up of patients [12] . Starting antiviral treatment with neuraminidase inhibitor during the first 2 days of symptoms has been shown to shorten influenza symptoms and prevent lower respiratory tract complication in influenza cases [9] . In this subgroup, Influenzatop® is a sound diagnostic alternative to the more expensive RT-PCR which is not readily available in all settings. Earlier on into the illness, negative results with rapid tests are not sufficient to exclude infection. In these cases, clinicians should make decision on the treatment, prophylaxis, and preventive measures based on clinical presentation, circulating subtypes, and their respective antiviral susceptibility patterns, as well as economic considerations.
